Status:
COMPLETED
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, an...
Detailed Description
see above
Eligibility Criteria
Inclusion
- Age 18-65 years old
- Primary Diagnosis of OCD
- Physically healthy and females must be using effective contraception
- At lease moderate OCD symptoms (Yale-Brown Obsessive-Compulsive Scale \[YBOCS\]score greater or equal to 16 prior to entering trial)
- Able to provide consent
- May be on or off selective reuptake inhibitor (SRI) medications
- Patients on an SRI medication will be included if the dose is stable and adequate (or if they don't want to increase their dose \[e.g. side effects\] and have a history of prior SRI or CBT treatment meeting criteria for adequate trial)
- Patients not on an SRI medication will be included if they they have failed at least 1 prior trial of standard OCD treatment (e.g. SRIs or CBT)
Exclusion
- Ongoing treatment with memantine
- Patients planning to start CBT during the study period or those who have started CBT within 8 weeks prior to study enrollment
- Presence of psychotic symptoms or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder.
- Current major depressive disorder (patients must be free of the disorder for three months prior to enrollment). Patients will be excluded if they are moderately to severely depressed, but if they are mildly to moderately depressed they will be included (Hamilton Depression Rating Scale must be \<18).
- Judged clinically to be at risk of suicide (suicidal ideation, severe depression, or other factors).
- Current eating disorder
- Females who are pregnant or nursing
- Severe renal insufficiency, severe hepatic impairment, or seizure disorder.
- Documented history of hypersensitivity or intolerance to memantine.
- Concomitant use of trimethoprim, N-methyl-D-aspartate receptor medications
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00956085
Start Date
August 1 2009
End Date
December 1 2015
Last Update
June 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032